Robert Abraham

Robert Abraham

Robert (Bob) is Senior Vice President and Group Head, Oncology – Rinat R&D. This group is at the forefront of breaking new ground to develop impactful, life-saving cancer therapies and spearheading the company’s Precision Medicine approach to R&D.

“This is an incredibly exciting time to be involved in cancer research and drug development. Advances in cancer biology and associated technologies are providing unprecedented insights into the biological underpinnings of this complex disease, and are opening novel approaches to attack specific vulnerabilities in tumor cells. Similarly, the dramatic increase in our understanding of the tumor-host relationship is fueling a much more comprehensive perspective of the systems biology of cancer. In particular, recent clinical successes in cancer immunotherapy have reinvigorated efforts to instigate the patient’s own immune system to selectively recognize and kill tumor cells. We are now entering an era in which we can realistically expect to develop therapies that induce very durable or even curative responses in patients afflicted with cancer that were previously considered incurable.”

Robert AbrahamPrior to this new role, Dr. Abraham served as Senior Vice President and Chief Scientific Officer of the Oncology Research Unit. Before joining Pfizer, Dr. Abraham was the Vice President of Oncology Research at Wyeth and Co-Chair of the Wyeth Oncology Therapeutic Area Strategic Committee. While at Wyeth, he also served as a member of the Discovery Review Board and the Discovery Executive Committee, and was the Director of the Wyeth Discovery Postdoctoral Training Program.

Before joining Wyeth, Dr. Abraham was a professor at the Sanford-Burnham Institute for Medical Research (SBIMR) in La Jolla, California. He served as the Director of the SBIMR Cancer Research Center and successfully guided the center to a renewal of its designation as one of nine National Cancer Institute-sponsored basic science centers in the United States.

Dr. Abraham also founded and directed the program in Signal Transduction Research in the SBIMR Cancer Center, and retains an appointment as an Adjunct Professor at the SBIMR, together with an Adjunct Professor Appointment in Pharmacology at the University of California, San Diego. Previously, Dr. Abraham was a professor in the Department of Pharmacology and Cancer Biology at Duke University Medical Center, and was the first recipient of the Glaxo-Wellcome Chair of Molecular Cancer Biology at Duke. Before his arrival at Duke University, Dr. Abraham began his independent research career at the Mayo Clinic, where rose from his initial position as a postdoctoral fellow to the rank of Professor in the Departments of Immunology and Pharmacology.

Dr. Abraham received his Ph.D. in pharmacology at the University of Pittsburgh, and his B.S. in Biology from Bucknell University. He is the author of more than 200 scientific publications, and has served on and chaired grant review panels at the National Institutes of Health. He is a reviewer for many leading scientific journals, including Nature, Science, and Cell.

Dr. Abraham has received several awards for both his teaching and research contributions, including the Legacy Laureate Award, as an outstanding alumnus of the University of Pittsburgh.

Bob ADC video

Hear Bob Abraham discuss antibody drug conjugates, a key technology focus in the Oncology Research Unit.